Completed PHASE1 INTERVENTIONAL 1-arm NCT04577703

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ningetinib (CT053PTSA) in Patients With Advanced Solid Tumors: A Phase I, Single-arm, Single-center, Open-label, Dose-escalation Study

Sponsor: Sunshine Lake Pharma Co., Ltd.

Conditions Advanced Solid Tumors

Interventions CT053PTSA

Updated 4 times since 2020 Last updated: Sep 30, 2020 Started: Feb 8, 2014 Primary completion: Dec 10, 2015 Completion: Dec 10, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumors and is currently completed. Sunshine Lake Pharma Co., Ltd. leads this study, which shows 4 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2020 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sunshine Lake Pharma Co., Ltd.

Data source: Sunshine Lake Pharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China